Centrient Hits Milestone On Antimicrobial Resistance
Semi-Synthetic Penicillin APIs Reach Target
Executive Summary
Centrient has declared itself one of the first companies to announce progress in achieving Predicted No-Effect Concentration discharge targets for the largest part of its antibiotics – the firm’s semi-synthetic penicillin active pharmaceutical ingredients portfolio. In addition, 97% of Centrient’s SSP finished-dose formulation products are also PNEC compliant, according to the firm.
You may also be interested in...
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
Centrient Hails Milestone For Clean Antibiotic Production
Centrient has celebrated passing a “significant milestone in the clean production of antibiotics” after meeting Predicted No Effect Concentration discharge targets set by the AMR Industry Alliance across its entire oral antibiotics product range.